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S U M M A R Y
Objectives: The role of a newly discovered bunyavirus, the severe fever with thrombocytopenia
syndrome virus (SFTSV), in the pathogenesis of severe fever with thrombocytopenia syndrome (SFTS) is
poorly understood. In this study, it was hypothesized that peripheral monocytes, which are constantly
exposed to viral infection in the blood, are likely targeted by the causative virus in SFTS patients.
Methods: Fifty-three patients and 25 healthy volunteers were enrolled in the study. Monocyte counts in the
peripheral blood of all human subjects were monitored throughout the progress of the disease. SFTSV viral
load and the expression of monocyte genes were investigated by real-time RT-PCR. Cytokine production of
monocytes in SFTS patients upon lipopolysaccharide (LPS) stimulation was examined by ELISA.
Results: In comparison to SFTS patients in the convalescent stage and healthy controls, monocyte cell
counts and percentages in patients at the acute stage were signiﬁcantly lower. Decreased monocyte cell
counts and subsets were positively correlated with SFTSV viral loads in the serum samples from SFTS
patients. Despite their higher basal toll-like receptor 4 (TLR4) expression, monocytes from patients in the
acute phase were shown to be compromised regarding the production of tumor necrosis factor alpha, but
not interleukin 10, upon LPS stimulation.
Conclusions: These data strongly suggest that monocytes could be a major target during SFTSV infection.
The decreased population and dysfunction of monocytes in acute SFTS patients may contribute to the
disease severity.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Severe fever with thrombocytopenia syndrome (SFTS) is an
emerging infectious disease characterized by unexplained hemor-
rhagic fever-like illnesses. The causative agent, the severe fever
with thrombocytopenia syndrome virus (SFTSV), also named
Huaiyangshan mountain virus, is a novel tick-borne Phlebovirus
classiﬁed within the Bunyaviridae family.1 SFTSV is a single-
stranded RNA virus, comprising three genes: L, M, and S.
Like other phleboviruses, SFTSV is transmitted mainly through
vectors (ticks) to humans in most cases. However, some reports* Corresponding author. Tel.: +86 027 85726398; fax: +86 027 85726398.
E-mail address: yingchunzhou@hust.edu.cn (Y. Zhou).
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0933-3657/$ – see front matter1201-9712/ 2015 The Authors. Published by Elsevier L
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-ndhave indicated that SFTSV can be transmitted from human to
human.2 Since SFTS was ﬁrst discovered in China in 2009,3 SFTSV
infection has spread to at least 16 Chinese provinces4,5 and other
East Asian countries, such as Japan6 and Korea.7 Patients with SFTS
have shown a broad spectrum of clinical manifestations, ranging
from an acute self-limited febrile illness to various grades of severe
presentation, including a fatal outcome and multiple organ failure.
Reported fatality rates vary between 12% and 30%.4,8 Leukopenia
and severe thrombocytopenia are the hallmarks of patients with
SFTS in laboratory tests.1,5 To date, neither effective antiviral
strategies nor conventional vaccines have provided sustainable
control of the spread of SFTSV.
A better understanding of the pathogenesis in SFTSV infection
will facilitate the development of more effective prevention and
control measures. Increasing evidence indicates that the immunetd on behalf of International Society for Infectious Diseases. This is an open access
/4.0/).
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determining the severity and clinical outcome of this disease.
Along these lines, the most severe SFTS patients are the elderly.1
Studies by Deng et al.9 and Sun et al.10 have demonstrated that
exaggerated immune activation and the overproduction of inﬂam-
matory cytokines such as interleukin (IL)-1b, IL-6, IL-10, tumor
necrosis factor alpha (TNF-a), and monocyte chemoattractant
protein-1 (MCP)-1 could create a ‘cytokine storm’, signiﬁcantly
contributing to the severity of SFTS. Various immune cell popula-
tions, including T lymphocytes and natural killer cells, have been
found to be skewed in SFTSV-infected patients, especially those in
the acute phase and the severe cases.11 These results suggest that
immunocompromised hematopoietic cells may contribute to the
severity and clinical outcome in SFTS patients.12,13
Circulating monocytes, constituting about 10% of leukocytes in
human blood, form a crucial part of the native immune system.
While functional monocytes can fend off various infections,
dysfunction of monocytes in immune-compromised individuals
may lead to increased severity of viral infections. For example,
monocytes, but not T- or B-cells, are the main targets of human
peripheral blood mononuclear cells for dengue virus.14 As for
SFTSV, splenic macrophages have been shown to harbor infected
viruses in a rodent model.15 A similar result was obtained from an
in vitro cell culture system using monocytic THP-1 cells.16 These
studies imply that monocytes/macrophages may support persis-
tent SFTSV viral infection. However, the evidence that monocytes/
macrophages are directly involved in the development of SFTS in
patients, particularly those in the acute phase, is still missing.
Both the clinical and biological aspects of monocytes in SFTSV-
infected patients were examined in this study. In addition, the
functions of these monocytes were analyzed by treating them with
a well-deﬁned toll-like receptor 4 (TLR4) ligand, lipopolysaccha-
ride (LPS). This study sheds some light on the pathological role of
SFTSV-infected monocytes in the development of the disease.
2. Methods
2.1. Human subjects
All patients were admitted to Union Hospital in Wuhan City
during the period April 20 to August 31, 2014. The diagnosis of SFTS
was conﬁrmed according to the clinical guidelines on severe fever
with thrombocytopenia syndrome released by the Ministry of
Health of the People’s Republic of China. In all, 53 patients who
developed SFTS (acute onset of high fever, leukopenia, and
thrombocytopenia) were included in this study. Healthy volun-
teers recruited into the study were from the local area and there
was no bias with respect to sex, age, or ethnic background.
All patients were admitted to the hospital on day 3 to day
6 following the onset of illness. Patients whose neutrophil granulo-
cytes were lower than 1  109/l were given recombinant human
granulocyte colony-stimulating factor (rhG-CSF; Qilu Pharmaceutical,
Jinan, China) at 2 mg/kg daily until counts reached more than
2.5  109/l. Details of the patients’ clinical history, physical examina-
tion, and routine hematology laboratory results were collected
retrospectively by physicians. Blood samples were collected from
patients in the acute and the convalescent phases from the date of
admission until the 10th day without fever. Serum and peripheral
blood mononuclear cells (PBMCs) obtained by Ficoll–Hypaque
centrifugation of blood, were prepared from both patients and healthy
subjects; these were used for further testing, as described below.
2.2. Monocyte preparation and cytokine detection
Human blood cells enriched in monocytes were isolated from
PBMCs by an adherence method. Brieﬂy, PBMCs from SFTS patientsor healthy volunteers were incubated in microexudate-treated
ﬂasks at 1  107 cells/ﬂask in RPMI 1640 containing 15% fetal
bovine serum (FBS) at 37 8C for 2 h. Non-adherent cells were
removed by repeat washing with phosphate buffered saline (PBS).
The adherent cells were tested for purity by ﬂow cytometry using a
monocyte-speciﬁc marker anti-CD14 mAb FITC (BD Biosciences,
San Jose, CA, USA) on a FACSCalibur instrument (BD Biosciences,
San Jose, CA, USA). Purity of >80% could be reached routinely. The
adherent cells were detached from the ﬂasks with a cell scraper
and stimulated with ultrapure LPS of an Salmonella minnesota
strain (1 mg/ml; InvivoGen, San Diego, CA, USA) at 5  105 cells/ml
in six-well plates for 18 h. The supernatant from these cultures
was collected and assayed for the expression of TNF-a and IL-10
using a commercial ELISA kit (Elabscience, Wuhan, China). The
detection limit for TNF-a was 8–1000 pg/ml and for IL-10 was
7.813–500 pg/ml.
2.3. RNA extraction, cDNA synthesis, and real-time RT-PCR
Total RNA was prepared from 0.5–2  106 puriﬁed monocytes
using the TRIzol method (Life Technologies, Carlsbad, CA, USA).
Single-stranded cDNA was synthesized using a PrimeScript
Reagent Kit (TaKaRa/Clontech, Mountain View, USA). The
quantitative real-time PCR was performed on a Bio-Rad Digital
PCR system with SYBR Premix Ex Taq II (TaKaRa/Clontech) in
50 ml reaction using 1 ml cDNA. Data were collected and analyzed
using QuantaSoft Software (TaKaRa/Clontech, Mountain View,
USA). Primers for the detection of TLR4 (NM_0032663) and
b-actin (ACTB) were purchased from GeneCopoeia (Rockville,
USA). The fold change was calculated according to the formula
2
DCT(gene)  DCT(ACTB).
2.4. SFTS viral load assay
Serum viral RNA was extracted from patient samples (1 ml)
using a viral RNA kit from DAAN Gene (Guangzhou, China); the
manufacturer’s procedures were followed. For intracellular viral
RNA, total RNA was similarly extracted from 0.5  106 puriﬁed
monocytes of SFTS patients and healthy controls, as described
above; the SFTSV viral load (number of copies of SFTSV viral RNA)
was determined by one-step real-time RT-PCR. A plasmid contain-
ing the full length of the SFTSV S segment was used as a standard
for calculation of the SFTSV genome copies. All reagents were
certiﬁed for clinical diagnostic use.
2.5. Statistical analysis
Continuous variables were recorded as the median (range) or
mean  standard error of the mean, unless indicated otherwise. Viral
loads were subjected to correlation analysis after logarithmic
transformation. The Mann–Whitney t-test was used to compare
variables between two independent groups. Statistical analyses were
performed using the Pearson Chi-square test or Fisher’s exact test in
tables to test relationships. Linear regression analysis was used to
assess the correlation of two variables. The statistical graphs were
constructed using GraphPad Prism 5.0 (GraphPad Software, San
Diego, CA, USA) and SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). A
two-tailed p-value of less than 0.05 (95% conﬁdence internal) was
considered statistically signiﬁcant.
2.6. Ethics statement
Written informed consent was obtained from all of the patients
and volunteer participants. This study was approved by the Review
Board of the Ethics Committee of Wuhan Union Hospital, Wuhan
City, China.
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3.1. Clinical and laboratory results at admission
Healthy individuals (n = 25) and SFTS patients (n = 53), includ-
ing 44 non-fatal and nine fatal cases, were enrolled in this study. All
patients were conﬁrmed for SFTSV infection as described above.
The median length of hospitalization for non-fatal cases was 10.4
(4–22) days. Most fatal cases died within 7 days after admission.
The fatality rate for SFTS patients was 17%. The results of
hematology laboratory tests for the healthy individuals and SFTS
patients at admission are summarized in Table 1. Consistent with
other reports,12,13 SFTS patients showed signiﬁcantly lower total
leukocyte and platelet counts at admission when compared to
healthy individuals (p < 0.0001). Within the subsets of leukocytes,
SFTSV infection was found to affect lymphocytes and neutrophils
less, as the percentages of these cells in blood were unchanged;
however, SFTSV affected monocytes signiﬁcantly, as the percent-
age of monocytes was reduced from 9.9% in healthy controls to
6.7% in SFTS patients (p = 0.0019).
There was no signiﬁcant difference between the fatal and non-
fatal cases among SFTS patients with respect to either the total
leukocyte count (p = 0.5433) or the percentages of the leukocyte
subsets. It is interesting to note, however, that the median age of
the fatal cases (64.1 years) was signiﬁcantly higher than that of the
non-fatal cases (52.2 years) (p = 0.0172).
3.2. Decreased monocyte cell counts and percentages in acute SFTS
patients
To further investigate the effect of SFTSV infection on monocyte
populations, data from all 53 SFTS patients and healthy subjects
were analyzed. For the SFTS patients, data were collected for both
the acute phase and the recovery phase. As shown in Figure 1, both
the monocyte counts (Figure 1A) and percentages of monocyte
subsets (Figure 1B) were signiﬁcantly lower in patients in the acute
stage when compared to those of healthy controls (p = 0.0026 and
p = 0.0037, respectively). Both parameters returned to normal
when patients were in the recovery phase (p = 0.0004 for the cell
counts and p < 0.0001 for the percentages of monocyte subsets).
To understand the dynamic changes in monocyte counts and
percentages of monocyte subsets during the course of disease, data
were collected from the non-fatal and fatal patients at different
time intervals for their entire hospital stays. In response to rhG-CSF
treatment, both the monocyte counts and percentages of
monocyte subsets in the non-fatal cases increased steadily,Table 1
Characteristics of healthy controls and SFTS patients at admission
Characteristic Healthy controls
(n = 25)
All patients
(n = 53)
Age, years 49.3 (28–69) 53.8 (24–79) 
Sex, male, n (%) 18 (60%) 30 (55.6%) 
Length of hospital stay, days - 9.0 (1.0–30.0) 
Leukocyte count, 109/l 5.89 (3.75–9.50) 3.11 (0.32–13.38) 
Neutrophil count, 109/l 3.61 (1.46–7.92) 2.08 (0.17–11.41) 
Lymphocyte count, 109/l 1.45 (0.61–3.63) 0.78 (0.12–1.57) 
Monocyte count, 109/l 0.43 (0.31–1.79) 0.21 (0.01–1.57) 
Neutrophil percentage % 60.3 (41.4–79.2) 63.8 (19.6–88.1) 
Lymphocyte percentage % 24.4 (11.1–41.8) 28.4 (5.3–64.7) 
Monocyte percentage % 9.9 (5.8–18.9) 6.7 (0.6–16.5) 
Platelet count, 109/l 192 (64–375) 54 (22–245) 
SFTS, severe fever with thrombocytopenia syndrome. Data are the median (range) unl
a Healthy controls versus patients.
b Non-fatal versus fatal cases.
c By means of the t-test.reaching the highest point on day 5, and then gradually leveled-
off through the remaining course of the illness (Figure 1C and 1D).
There was a lesser degree of increase in both parameters in the
fatal cases as patients died within 7 days of hospitalization.
3.3. Decreased monocyte cell counts and percentages were correlated
with increased serum viral loads in acute SFTS patients
To address the relationship between skewed monocyte
frequencies and other clinical parameters, several linear regression
analyses were conducted with the 26 acute SFTS patients. As
shown in Figure 1 (E and F), there was a signiﬁcant inverse
correlation between these two monocyte parameters and serum
SFTSV viral loads (r = 0.54, p = 0.0034 for cell counts; r = 0.483,
p = 0.0092 for subset percentages). There was no signiﬁcant
correlation between these two monocyte parameters and alanine
aminotransferase (ALT), aspartate aminotransferase (AST), sex,
age, or other clinical indexes (data not shown).
SFTSV viral loads were also analyzed in the monocytes and
serum samples from 10 acute SFTS patients. The results indicated
that the number of SFTSV genome copies found in patient
monocytes was comparable to that found in the serum of the
same patient. Linear regression analyses of SFTSV loads in
monocytes and in the sera from the same group of patients
indicated that patients with higher serum viral loads also showed
higher monocyte viral loads (Figure 2; R = 0.90, p = 0.0003). This
result suggests that the viral load in monocytes and that in the
serum of acute SFTSV-infected patients are positively correlated.
3.4. Monocytes puriﬁed from acute SFTS patients exhibited impaired
TNF-a production in response to LPS stimulation
Whether the loss of the monocyte population is associated with
monocyte dysfunction in SFTS patients was examined next. To
address this question, a well-deﬁned ligand for TLR4 – LPS – was
added to cultured monocytes isolated from patients in the acute
phase (n = 10), from the same patients in the recovery phase
(n = 10), and from healthy controls (n = 10). TLRs are pattern
recognition receptors capable of sensing a broad range of microbial
and viral products and producing large quantities of cytokines;
they play important roles in the eradication of pathogens.17 Two
cytokines were chosen for the study, an inﬂammatory cytokine
(TNF-a) and an immunosuppressive cytokine (IL-10). The expres-
sion of these cytokines in monocytes was determined by ELISA.
SFTSV viral load assays indicated that viral genomes were only
found in monocytes from patients in the acute stages, but not inp-Valuea All patients p-Valueb
Non-fatal (n = 44) Fatal (n = 9)
0.1092c 52.2 (24–79) 64.1 (51–71) 0.0172c
0.0331 26 (57.8%) 4 (44.4%) 0.0955c
- 10.4 (4–22) 5.8 (3–11) 0.0015c
<0.000c 3.18 (0.83–13.38) 2.65 (0.32–6.81) 0.5433c
<0.000c 2.08 (0.2–11.41) 1.99 (0.17–4.75) 0.9090c
<0.000c 0.83 (0.21–3.74) 0.47 (0.12–1.19) 0.1364c
<0.000c 0.23 (0.01–1.57) 0.12 (0.01–0.12) 0.2431c
0.9802c 62.1 (19.6–91.4) 74.3 (53.1–88.1) 0.0783c
0.3305c 29.8 (5.3–64.7) 19.8 (9.1–37.5) 0.0831c
0.0019c 7.1 (0.6–16.5) 4.6 (0.7–9.4) 0.1192c
<0.000c 56 (22–245) 47 (23–90) 0.457c
ess speciﬁed otherwise.
Figure 1. Decreased monocyte counts and percentages in acute SFTS patients correlated with serum SFTSV viral loads. (A) and (B): monocyte counts and percentages of acute
SFTS patients (n = 53) were compared to those of healthy controls (n = 25) and patients in the recovery stage (n = 44) by Mann–Whitney t-test; a p-value of <0.05 is
considered statistically signiﬁcant. (C) and (D): dynamic changes in monocyte counts and percentages in both non-fatal cases (circles, n = 44) and fatal cases (squares, n = 9).
These two parameters were analyzed at different time intervals for the entire hospital stay. Results are shown as the median and the range of groups. (E) and (F): decreased
monocyte counts and percentages were closely associated with increased serum viral loads in SFTS patients. The results were obtained by linear regression analysis from
26 SFTS patients.
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(Figure 3A). As shown in Figure 3B, LPS was capable of stimulating
the production of TNF-a from all three groups. However, the
induction of TNF-a in patients in the acute stage was signiﬁcantly
reduced (mean 450 pg/ml) when compared to that in healthy
controls (mean >1000 pg/ml) (p = 0.0041). When patients were in
the recovery phase, the expression of TNF-a returned signiﬁcantly
to levels indistinguishable from those of the control group
(p = 0.0330). Similarly, the immunosuppressive cytokine IL-10
was induced in all three groups of subjects. However, there was noFigure 2. SFTSV viral loads in monocytes positively correlated with those in the
serum from acute SFTS patients. Monocytes and serum from the same group of
acute SFTS patients (n = 10) were analyzed for viral loads. Results were obtained by
linear regression analysis.signiﬁcant difference with respect to IL-10 induction between the
three groups upon LPS stimulation (Figure 3C).
3.5. TNF-a levels in LPS-stimulated monocytes were negatively
correlated with those in serum from acute SFTS patients
TNF-a and IL-10 levels were also determined in the sera from the
same groups of human subjects. In accordance with other
reports,9,10 the expression of both cytokines was found to be
signiﬁcantly elevated in the serum of acute SFTS patients (Figure 3D,
p = 0.0402 for TNF-a; Figure 3E, p = 0.0167 for IL-10). The expression
of both cytokines in patients in the recovery stage was found to be
reduced to levels similar to those of the healthy controls.
Interestingly, the expression of TNF-a in monocytes of acute SFTS
patients in response to LPS stimulation showed a signiﬁcantly
negative correlation with that in the sera from the same group of
patients (Fig. 3F; r = 0.71, p = 0.0219). However, the expression
of monocyte-derived TNF-a was not linked to the concentration of
serum IL-10 (Figure 3G; r = 0.13, p = 0.7238) or serum SFTSV viral
load (Figure 3H; r = 0.26, p = 0.4368).
3.6. Increased TLR4 RNA expression in monocytes from acute SFTS
patients
To investigate whether the decreased LPS stimulatory effect is
due to defective TLR4 expression in monocytes from SFTS patients,
TLR4 RNA levels were examined in SFTS patients in both the acute
and the recovery phases using a quantitative real-time RT-PCR. The
expression of TLR4 mRNA was four- to ﬁve-fold higher in the
monocytes from acute SFTS patients than in the monocytes from
healthy controls (p = 0.0366) (Figure 4); the expression decreased
drastically to the normal level when patients were in the recovery
phase (p = 0.0496), suggesting that the pathogen-sensing function
of monocytes in acute SFTS patients was intact. No relationship
Figure 3. Decreased TNF-a production in monocytes from acute SFTS patients in response to LPS stimulation. (A) Viral load assay on monocytes from healthy controls and
SFTS patients in the acute phase or in the recovery phase. (B) and (C): decreased TNF-a production but not IL-10 production in monocytes from acute SFTS patients in response
to LPS stimulation. Monocytes isolated from healthy individuals (n = 10) and a group of SFTS patients (n = 10) at either the acute or the recovery stage were adjusted to
5  105/ml and stimulated with 1 mg/ml TLR4 agonist, LPS, for 18 h. The levels of TNF-a (B) and IL-10 (C) production in the culture medium (1 ml) were evaluated by ELISA.
(D) and (E): increased serum levels of TNF-a and IL-10 in acute SFTS patients. The levels of serum TNF-a and IL-10 from the same human subjects, described in parts (B) and
(C), were analyzed. Note that the levels of TNF-a and IL-10 in serum were at least 50-fold lower when compared to those from stimulated monocytes (parts (B) and (C)). (F),
(G), and (H): relationships between levels of TNF-a in stimulated monocytes and those of serum TNF-a (F), serum-IL-10 (G), and serum SFTSV viral load (H). Serum samples
and puriﬁed monocytes from acute SFTS patients (n = 10) were analyzed for the expression of TNF-a, IL-10, and SFTSV viral load. Levels of LPS-induced monocyte-secreted
TNF-a were negatively correlated to those of serum TNF-a in the same group of patients (r = 0.71, p = 0.0219).
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TNF-a, IL-10, or other clinical indexes (data not shown).
4. Discussion
In this study, the clinical and hematological laboratory
parameters of SFTS patients in both the acute and recovery phasesFigure 4. Increased TLR4 mRNA expression in monocytes from acute SFTS patients.
Expression of TLR4 mRNA was measured in monocytes isolated from healthy
individuals (n = 10), from SFTS patients in the acute phase (n = 10), and from the
same patients in the recovery phase (n = 10) by quantitative real-time PCR. The
expression of b-actin was used as an internal control.were analyzed. In agreement with studies performed by others,1,8
it was found that the median age of fatal patient cases (64.1 years)
was signiﬁcantly higher than that of non-fatal cases (52.2 years)
(p = 0.0172). This suggests that patient age is an important
contributing factor to the development of illness.
Identifying the target cells of SFTSV infection is critical to
uncovering the pathogenesis of SFTS. Although it is well known that
SFTSV infections are associated with leukopenia and thrombocyto-
penia, the roles of each subset of peripheral leukocytes in the
pathogenesis of SFTSV infection remain unclear. In this study, it was
found that monocytes were disproportionately affected by SFTSV
infection (Table 1). Decreased monocyte cell counts and percentages
were associated with increased SFTSV viral loads in both the serum
(Figures 1E and 1F) and monocytes (data not shown) of patients,
suggesting that these cells are highly susceptible to SFTSV infection.
This study is the ﬁrst to report that peripheral monocytes may be the
primary target during SFTSV infection.
Decreased healthy monocyte populations during SFTSV infec-
tion may lead to compromised innate immunity, contributing to
the pathogenesis of the disease. Since patients with decreased
monocytes also showed increased SFTSV viral loads, it seems
plausible that the replication of SFTSV inside monocytes causes cell
death, leading to a depletion of monocyte cell subsets. However,
this possibility is not supported by the ﬁndings of Qu et al.,16 who
showed that the replication of SFTSV was not cytopathic to
cultured THP-1 monocytic cells.
In addition to the loss of cell populations, the dysfunction of
surviving monocytes after SFTSV infection may also contribute to
the development of the disease. The weak responsiveness of active
SFTSV-infected monocytes to LPS challenge (Figure 3B) when
compared to those from healthy controls and patients in the
recovery stage, suggests that these cells are immunologically
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to the pathogenesis of viral infection by protecting viruses from
eradication by other types of immune cells in patients, and by
carrying viruses through the lymphatic drainage, spreading them
into the circulation, thereby leading to viremia and multiple organ
failure. To date, the precise roles of peripheral monocytes in the
pathogenesis of SFTS remain unknown.
The mass production of proinﬂammatory cytokines can cause
multiple organ failure and this is clearly correlated with the
severity of disease in SFTS patients.9,10,12,13 In agreement with the
‘cytokine storm’ proposed by others,9,10 it was found that both
TNF-a and IL-10 were elevated in the sera from acute SFTSV-
infected patients (Figure 3, D and E). In striking contrast,
monocytes from the same group of patients showed a drastic loss
of ability to produce TNF-a in response to LPS stimulation
(Figure 3B); patients with higher levels of TNF-a in serum showed
reduced amounts of monocyte-derived TNF-a (Figure 3F). These
ﬁndings clearly indicate that virus-infected monocytes were not
major sources of TNF-a found in the serum of acute SFTS patients
and that other types of cell may account for the virus-induced
‘cytokine storm’. Toward this end, it is well known that
proinﬂammatory cytokines can be produced by a variety of
activated mononuclear/neutrophil cells or endothelial cells during
viral infection.18,19
Understanding the interaction of monocytes with SFTSV may
provide important insights into the pathogenesis of SFTS.
Increased TLR4 expression (Figure 4) in monocytes from acute
SFTS patients supports the notion that these cells are capable of
detecting active viral replication. However, in the presence of its
cognate ligand LPS, increased TLR4 expression in active SFTSV-
infected monocytes failed to mount a strong induction of the
proinﬂammatory cytokine TNF-a, a typical response found in
monocytes from healthy controls and patients in the recovery
stages (Figure 3B). The induction of anti-inﬂammatory cytokine
IL-10, on the other hand, was found to be unchanged (Figure 3C).
The impairment of monocytes with regard to the production of
TNF-a but not IL-10 suggests that the immune balance is skewed
by viral replication in the monocytes of acute SFTS patients.
Because of the limited availability of clinical specimens, it was
not possible to directly address the mechanism in vivo by which
the cytokine proﬁles of monocytes are modiﬁed in SFTSV
infection. The studies by Qu et al.16 demonstrated that one of
the SFTSV gene products, the nucleoprotein N, was capable of
inhibiting both interferon and nuclear factor kappa B (NF-kB)
responses in SFTSV-infected THP-1 cells. Since the synthesis of
TNF-a is absolutely NF-kB/TLR signaling pathway-dependent,20
it is speculated that the same viral-mediated inhibitory effect on
NF-kB may cause down-regulation of inﬂammatory cytokines in
SFTSV-infected monocytes, leading to an imbalanced cytokine
proﬁle. Further in-depth in vitro mechanistic studies are required
to clarify this issue.In summary, this study clearly showed the signiﬁcant loss of
monocyte subsets and functional impairment of monocytes as
consequences of acute SFTSV infection. The results suggest that the
involvement of monocytes in the pathogenesis of SFTS is through
a mechanism involving a disturbance of the innate immune
response.
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